β-amino acid substitution in the SIINFEKL antigen alters immunological recognition
We conclude that even though α/β analogues of the SIINFEKL antigen can elicit a T cell-based response, this class of backbone-modified peptides is not promising from the perspective of antitumor vaccine development.
Authors
- Douglas G. McNeel (ORCID: https://orcid.org/0000-0003-1471-6723)
- Samuel H. Gellman (ORCID: https://orcid.org/0000-0001-5617-0058)
- Ichwaku Rastogi (ORCID: https://orcid.org/0000-0003-1957-1164)
- John Sidney (ORCID: https://orcid.org/0000-0002-0987-405X)
- Ruslan Gibadullin (ORCID: https://orcid.org/0000-0001-8439-0218)
- Jena E. Moseman (ORCID: https://orcid.org/0000-0001-6849-3225)
- A Sette
- John A. Mannone (ORCID: https://orcid.org/0000-0002-4741-007X)
Institutions
- La Jolla Institute for Immunology (US)
- University of Wisconsin–Madison (US)
- University of California System (US)
Publication Details
- Journal
- Cancer Biology & Therapy
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1080/15384047.2025.2486141
- Citations
- 2
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.59
Funders
- Wisconsin Alumni Research Foundation
- University of Wisconsin-Madison